• Tue. Jun 22nd, 2021

Dimancherouge

Technology

Therapeutics

  • Home
  • A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics

A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for solid tumor cancer patients, today announced the closing of its $71.5M Series B financing. Proceeds will fund the advancement…

Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense

Award will support advancement of ALV-304 into the clinic for the potential treatment of inflammatory bowel disease Alivio Therapeutics, a biotechnology company developing an inflammation-targeting disease immunomodulation platform for the…

Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics

Genuity Science’s approach combines high-quality, whole-genome sequence and deep phenotype data resulting in better definition of the underlying disease mechanisms. This approach, when coupled with Ionis’ proprietary antisense technology, has…

Pain Therapeutics Market 2020: Business Trends, COVID – 19 Outbreak, Emerging Technologies, Growth Opportunities and Regional Forecast to 2025

The MarketWatch News Department was not involved in the creation of this content. Sep 28, 2020 (TS Newswire via Comtex) — KD Market Insights has published a report on global…